**Journal of Hepatology**

**CTAT methods**

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

* Only include the parts relevant to your study
* Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
* Do not add subheadings
* Add as many rows as needed to include all information
* Only include one item per row

**If the CTAT form is not relevant to your study, please outline the reasons why:**

|  |
| --- |
|  |

* 1. **Antibodies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name** | **Citation** | **Supplier** | **Cat no.** | **Clone no.** |
| CD14 |  | BD | 557742 | M5E2 |
| CD16 |  | BD | 560195 | 3G8 |
| CD163 |  | Invitrogen | 556018 | GHI/61 |
| CCR2 |  | Biolegend | 357226 | K03602 |
| HLA-DR |  | Invitrogen | 45-9956-42 | LN3 |
| MerTK |  | R&D System | FAB8912A | 125518 |
| CD155 |  | Biolegend | 337632 | SKII.4 |
| PD-L1 |  | Biolegend | 329724 | 29E.2A3 |
| PD-1 |  | BD | 563789 | EH12.1 |
| CD3 |  | eBioscience | 48-0036-42 | SK7  |
| Tim-3 |  | Biolegend | 345024 | F38-2E2 |
| TIGIT |  | eBioscience | 11-9500-42 | MBSA43  |
| CTLA-4 |  | eBioscience | 12-1529-42 | 14D3 |
| CD25 |  | BD | 562403 | M-A251 |
| CD127 |  | Invitrogen | 25-1278-42 | eBioRDR5 |
| CD8 |  | Invitrogen | 17-0088-42 | RPA-T8 |
| CD4 |  | Biolegend | 344616 | SK3 |
| CD45 |  | Biolegend | 304009 | HI30 |
| CD56 |  | Biolegend | 398808 | QA18A21 |
| ATX |  | abcam | ab77104 | 1F8 |

* 1. **Cell lines**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Name** | **Citation** | **Supplier** | **Cat no.** | **Passage no.** | **Authentication test method** |
| **N/A** |  |  |  |  |  |

* 1. **Organisms**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name** | **Citation** | **Supplier** | **Strain** | **Sex** | **Age** | **Overall n number** |
| **N/A** |  |  |  |  |  |  |

* 1. **Sequence based reagents**

|  |  |  |
| --- | --- | --- |
| **Name** | **Sequence** | **Supplier** |
|  |  |  |

* 1. **Biological samples**

|  |  |  |
| --- | --- | --- |
| **Description** | **Source** | **Identifier** |
| Plasma, Serum, PBMC | Patients | Anonymised |

* 1. **Deposited data**

|  |  |  |
| --- | --- | --- |
| **Name of repository** | **Identifier** | **Link** |
| Data can be made available at reasonable request |  |  |

* 1. **Software**

|  |  |  |
| --- | --- | --- |
| **Software name** | **Manufacturer** | **Version** |
| Flow-JO | Becton Dickinson & Company | v10 |
| Prism | Graphpad | v8.2.1 |
| SIMCA |  | v16 |
| Metaboanalyst  | <http://www.metaboanalyst.ca/> |  |
| QIAGEN Ingenuity Pathway Analysis | QIAGEN IPA |  |
| fastqc | <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/> | v0.11.9 |
| R | R Statisical Foundation, Vienna, Austria | v4.0.4 |
| trimgalore | <https://github.com/FelixKrueger/TrimGalore> | v0.6.5 |
| limma-voom | limma | v3.46.0 |
| Generally Applicable Gene-set Enrichment for Pathway Analysis | GAGE | v2.40.2 |

* 1. **Other (e.g. drugs, proteins, vectors etc.)**

|  |  |  |
| --- | --- | --- |
| H2L5186303 | Sigma-Aldrich |  |
| Ro 6842262 | Bio-techne |  |
| Ki 16425 | Sima-Aldrich |  |
| LPA 16:0, LPA 18:0, LPA 18:1, LPC 16:0, LPC 18:0 | Avanti Polar Lipids, Alabaster, AL |  |
|  |  |  |
|  |  |  |
|  |  |  |

* 1. **Please provide the details of the corresponding methods author for the manuscript:**

|  |
| --- |
| Dr Francesca M Trovato, PhDClinical Research Fellow in Liver Intensive CareInstitute of Liver Studies, School of Immunology & Microbial Science, Kings College London, SE5 9RS Denmark Hill, Londonfrancesca.trovato@kcl.ac.uk+4402032996280Dr Mark McPhail PhD MRCP FFICMSenior Lecturer and Honorary Consultant in Liver Critical Care & HepatologyInstitute of Liver Studies, School of Immunology & Microbial Science, Kings College London, SE5 9RS Denmark Hill, Londonmark.mcphail@kcl.ac.uk+4402032996280 |

**2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.**

|  |
| --- |
|  |